bioAffinity stock soars after receiving patent allowance for AI lung cancer test

bioAffinity Technologies Inc (NASDAQ:BIAF) stock surged 14% after the company announced it received a patent allowance from the U.S. Patent and Trademark Office for its AI-built algorithm and flow cytometry platform for early-stage lung cancer detection. The patent covers a system and method for predicting lung cancer likelihood by analyzing patient sputum samples, leveraging the company's CyPath® Lung test to detect cancer at potentially curative Stage 1A. This development significantly strengthens bioAffinity's intellectual property, adding to its global portfolio of 18 awarded and 33 pending patents, and highlights the potential for its technology in addressing a leading cause of cancer death.

Analysis

bioAffinity Technologies Inc (NASDAQ:BIAF) experienced a significant 14% stock surge on Thursday following the announcement of a patent allowance from the U.S. Patent and Trademark Office. This patent specifically covers the company's AI-built algorithm and flow cytometry platform, designed for early-stage lung cancer detection. The positive market reaction reflects investor recognition of this intellectual property milestone.

The newly allowed patent, titled "Detection of Early-Stage Lung Cancer in Sputum using Automated Flow Cytometry and Machine Learning," underpins bioAffinity's CyPath® Lung test. This technology aims to predict lung cancer likelihood by analyzing patient sputum samples, enabling detection at the potentially curative Stage 1A. The company emphasizes the integral role of artificial intelligence in developing this test, addressing a critical medical need given that lung cancer is projected to affect a quarter of a million Americans in 2025 and remains the leading cause of cancer death.

This U.S. patent significantly strengthens bioAffinity's intellectual property portfolio, which now comprises 18 awarded and 33 pending patents across multiple international jurisdictions. The expansion of its global patent estate provides a competitive moat and validates the company's innovative approach in the biotechnology sector. This development enhances the company's fundamental value and long-term market positioning within the diagnostic space.

Key Decisions for Investors

• Investors should closely monitor bioAffinity's progress in commercializing its CyPath® Lung test, given the strong patent protection and the significant market need for early lung cancer detection.
• Evaluate the company's ability to translate this intellectual property into revenue growth and market share, particularly as the global patent estate expands.
• Consider the long-term competitive advantages conferred by the AI-driven diagnostic platform and its potential to disrupt the lung cancer screening market.